Kymera Therapeutics Inc at Goldman Sachs Global Healthcare Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Chris Morguram - Goldman Sachs - Analyst : I think to kind of level set and start the conversation, if we could start by understanding the targeted protein degradation space a little bit more. Could you give us an overview of your technology and approach and how protein degraders differ from more perhaps conventional approaches?

Question: Chris Morguram - Goldman Sachs - Analyst : You know, that was great. And could you speak a little bit more to how your approach to target selection works, especially given the fact that you've had kind of a shift in terms of the focus strategically for the company in moving from oncology versus now the new prioritization of I&I more broadly.

Question: Chris Morguram - Goldman Sachs - Analyst : Digging a little bit more into specific assets. Let's shift gears a little bit towards KT-474, or IRAK4 degrader. A great segue there. First, if you could kind of walk us through your clinical proof-of-concept data that you saw in the Phase 1, how put the data in context relative to the standard of care?

Question: Chris Morguram - Goldman Sachs - Analyst : And how are you and your partner Sanofi thinking about how and where this oral agent could perhaps fit in the treatment algorithm? And how is that influencing your later-stage trial design strategy?

Question: Chris Morguram - Goldman Sachs - Analyst : For dosing, you've talked about responses that could deepen over time with chronic dosing. What have you learned about the kinetics of your drug so far? What can you expect based on the Phase 1 experience? And how do these compare to the standard of care other drugs in development?

Question: Chris Morguram - Goldman Sachs - Analyst : Timing. I am going to slightly push my luck just a little bit here, but you have mentioned that data from both studies will be coming likely in one half '25, atopic derm in January and HS estimated to complete in February of 2025. Could these data come potentially at the same time? Help us -- perhaps understand what we'll learn about the results? Would you expect that you and Sanofi will be able to send out a press release with top-line results with details at a specific medical meeting? What's kind of the goal here?

Question: Chris Morguram - Goldman Sachs - Analyst : Right, makes sense. I guess moving a little bit further into your pipeline. So you have KT-621, which is your STAT6 degrader. Could you give us an overview of this program which is set to enter the clinic second half of this year. How does the pre-clinical data in mice and nonhuman primates look from a PK and safety perspective? What are perhaps the rate-limiting steps to getting this into patients?

Question: Chris Morguram - Goldman Sachs - Analyst : KT-294, your TYK2 degrader, which is set to enter the clinic in the first half of 2025. Can we talk about this drug's profile versus approved deuterated TYK2 inhibitor, deucravacitinib or other tech two inhibitors in development, including from Takeda or other private companies like Illumina Therapeutics or Sudo Biosciences?

Question: Chris Morguram - Goldman Sachs - Analyst : You now makes complete sense. Shifting a little bit more to your oncology assets. KT-333, your STAT3 your degrader, where will you present data in a poster for STAT3 degrader. KT-333 and EHA this week, can you characterize the clinical data that you've shown so far and what we should expect at the EHA conference versus what was in the abstract?

Question: Chris Morguram - Goldman Sachs - Analyst : Looking broader to the competitive landscape. Can you talk about the challenges the field has faced when targeting STAT3 transcription factor and why you believe degradation presents an advantage?

Question: Chris Morguram - Goldman Sachs - Analyst : Saving the best for last, MDM2 degrader, KT-253. You recently presented initial proof of concept data at ASCO for this asset. Can you give us key takes from dose escalation data where you saw clinical activity, including two partial responses and one complete response at dose levels one and two, respectively?

Question: Chris Morguram - Goldman Sachs - Analyst : Perfect. Thank you. Zooming out a little bit more to the strategy and overall business development aspects of Kymera. What are your current partnering plans for non-partnered assets in I&I, STAT6, TYK2, et cetera. Any color here? without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated companies. JUNE 11, 2024 / 6:40PM, KYMR.OQ - Kymera Therapeutics Inc at Goldman Sachs Global Healthcare Conference

Question: Chris Morguram - Goldman Sachs - Analyst : Short and sweet.

Question: Chris Morguram - Goldman Sachs - Analyst : So for particularly oncology, where you've shown initial clinical data and partnerships are key to perhaps further developments. How do you think about priorities moving forward in terms of investment between your many programs?

Question: Chris Morguram - Goldman Sachs - Analyst : You are well capitalized with $745 million approximately. without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated companies. JUNE 11, 2024 / 6:40PM, KYMR.OQ - Kymera Therapeutics Inc at Goldman Sachs Global Healthcare Conference

Question: Chris Morguram - Goldman Sachs - Analyst : Last time I checked.

Question: Chris Morguram - Goldman Sachs - Analyst : With runway into the first half of 2027. What does that runway entail, how can we think about bringing new candidates into your pipeline, including potentially a molecular glue asset?

Question: Chris Morguram - Goldman Sachs - Analyst : I'm going to squeeze one last question in here. Any color for the balance of the year on what your capital allocation priorities will be?

Question: Chris Morguram - Goldman Sachs - Analyst : Well, on that note, thank you so much. My name is Chris [Morguram], here with the Goldman team. Welcome to Miami. Have a wonderful rest of your day, everyone.

Question: Chris Morguram - Goldman Sachs - Analyst : I know he would home.